Abstract：
UNASSIGNED: The factors determining the response to treatment with glucagon-like peptide-1 receptor agonists (GLP-1- RAs) have not been clarified. The present study investigated the association between polymorphisms in TCF7L2, CTRB1/2, and GLP-1 R genes and response to GLP-1 RAs regarding glycemic control and weight loss among Greek patients with type 2 diabetes mellitus (T2DM).
UNASSIGNED: Patients (n = 191) treated with GLP-1 RAs for at least 6 months were included. Participants were genotyped for TCF7L2 rs7903146 (C>T), CTRB1/2 rs7202877 (T>G) and GLP-1 R rs367543060 (C>T) polymorphisms. Clinical and laboratory parameters were measured before, 3, and 6 months after treatment initiation. The patients were classified into responders and non-responders according to specific criteria.
UNASSIGNED: Carriers of at least one rs7903146 \'T\' allele and rs7202877 \'G\' allele presented similar glucose control and weight loss response to GLP-1 RAs with the respective homozygous wild-type genotypes [odds ratio (OR): 1.08, 95% confidence interval (CI): 0.5, 2.31, p = 0.85 and OR: 1.35, 95% CI: 0.66, 2.76, p = 0.42; OR: 1.4, 95% CI: 0.56, 3.47, p = 0.47 and OR: 1.28, 95% CI: 0.55, 2.98, p = 0.57, respectively]. Regarding the GLP-1 R polymorphism, all participants were homozygous for the wild-type allele; thus, no comparisons were feasible. Female sex (p = 0.03) and lower baseline weight (p = 0.024) were associated with an improved glycemic and weight loss response, respectively.
UNASSIGNED: There is no evidence suggesting a role for the variants studied in response to GLP-1 RA therapy in people with T2DM. However, specific demographic and clinical factors may be related to a better response to treatment with these agents.
UNASSIGNED: Patients (n = 191) treated with GLP-1 RAs for at least 6 months were included. Participants were genotyped for TCF7L2 rs7903146 (C>T), CTRB1/2 rs7202877 (T>G) and GLP-1 R rs367543060 (C>T) polymorphisms. Clinical and laboratory parameters were measured before, 3, and 6 months after treatment initiation. The patients were classified into responders and non-responders according to specific criteria.
UNASSIGNED: Carriers of at least one rs7903146 \'T\' allele and rs7202877 \'G\' allele presented similar glucose control and weight loss response to GLP-1 RAs with the respective homozygous wild-type genotypes [odds ratio (OR): 1.08, 95% confidence interval (CI): 0.5, 2.31, p = 0.85 and OR: 1.35, 95% CI: 0.66, 2.76, p = 0.42; OR: 1.4, 95% CI: 0.56, 3.47, p = 0.47 and OR: 1.28, 95% CI: 0.55, 2.98, p = 0.57, respectively]. Regarding the GLP-1 R polymorphism, all participants were homozygous for the wild-type allele; thus, no comparisons were feasible. Female sex (p = 0.03) and lower baseline weight (p = 0.024) were associated with an improved glycemic and weight loss response, respectively.
UNASSIGNED: There is no evidence suggesting a role for the variants studied in response to GLP-1 RA therapy in people with T2DM. However, specific demographic and clinical factors may be related to a better response to treatment with these agents.
摘要：
决定对胰高血糖素样肽-1受体激动剂(GLP-1-RA)治疗的反应的因素尚未阐明。本研究调查了2型糖尿病（T2DM）希腊患者中TCF7L2，CTRB1/2和GLP-1R基因多态性与对GLP-1RA的反应之间的关联。
■包括用GLP-1RA治疗至少6个月的患者(n=191)。参与者被基因分型为TCF7L2rs7903146（C>T），CTRB1/2rs7202877(T>G)和GLP-1Rrs367543060(C>T)多态性。之前测量了临床和实验室参数，治疗开始后3个月和6个月。根据具体标准将患者分为应答者和非应答者。
■至少一个rs7903146\'T\'等位基因和rs7202877\'G\'等位基因的携带者对GLP-1RA的葡萄糖控制和体重减轻反应分别具有相应的纯合野生型基因型[比值比（OR）：1.08，95％置信区间（CI）：0.5，2.31，p=0.85％CI：0.35，p=0.66，0.66关于GLP-1R多态性，所有参与者都是野生型等位基因纯合的；因此，没有比较是可行的。女性（p=0.03）和较低的基线体重（p=0.024）与改善的血糖和体重减轻反应相关。分别。
■没有证据表明所研究的变异体在2型糖尿病患者中对GLP-1RA治疗的应答中的作用。然而,特定的人口统计学和临床因素可能与这些药物治疗效果更好有关.
■包括用GLP-1RA治疗至少6个月的患者(n=191)。参与者被基因分型为TCF7L2rs7903146（C>T），CTRB1/2rs7202877(T>G)和GLP-1Rrs367543060(C>T)多态性。之前测量了临床和实验室参数，治疗开始后3个月和6个月。根据具体标准将患者分为应答者和非应答者。
■至少一个rs7903146\'T\'等位基因和rs7202877\'G\'等位基因的携带者对GLP-1RA的葡萄糖控制和体重减轻反应分别具有相应的纯合野生型基因型[比值比（OR）：1.08，95％置信区间（CI）：0.5，2.31，p=0.85％CI：0.35，p=0.66，0.66关于GLP-1R多态性，所有参与者都是野生型等位基因纯合的；因此，没有比较是可行的。女性（p=0.03）和较低的基线体重（p=0.024）与改善的血糖和体重减轻反应相关。分别。
■没有证据表明所研究的变异体在2型糖尿病患者中对GLP-1RA治疗的应答中的作用。然而,特定的人口统计学和临床因素可能与这些药物治疗效果更好有关.
